Fighting cancer means making sense of complex patient data in real time.
Artificial intelligence (AI) is helping doctors understand robust datasets in radically new ways. We’ve developed FetchTM, an AI-powered tool that delivers unmatched insight into dog cancer mutations and the effectiveness of treatments for each. It enables greater evidence-based treatment decisions for dogs battling cancer. The result is more individualized treatment plans that maintain a higher quality of life for each patient.
Cancer is the leading cause of death in dogs, with over 6 million dogs diagnosed annually in the U.S. By leveraging AI and targeted therapies, FidoCure is not just fighting cancer, we’re seeking to preserve the everlasting bonds between pets and their people.
Driving our approach to canine cancer treatment is the basic principle that any pet going through treatment should maintain the highest quality of life possible. When a dog is diagnosed with cancer, traditional treatments like chemotherapy are challenging experiences. Chemotherapy is cytotoxic, meaning it indiscriminately kills cancer and healthy cells. This can lead many pet parents to discontinue them before the cancer is eliminated.
Each cancer is as unique as the dog battling it. FidoCure’s precision medicine recognizes this by analyzing the specific genetic mutations of each dog’s cancer before recommending a tailored treatment plan. This plan will typically deliver treatment doses that seek maximum efficacy at a low enough dosage where side effects are minimized.
Ask any pet parent, and you’ll find that the human-animal bond is one of the strongest connections on Earth. It’s a relationship built on unconditional love and companionship. As with any profound bond, pet parents will do anything for their canine companions. That’s especially true if it involves giving them a second chance at life in the face of a cancer diagnosis. But what good is fighting cancer if it compromises our beloved pets’ quality of life?
We baked quality of life and the safety of our patients directly into the design of our FetchTM AI engine. FetchTM analyzes over 2 billion data points from 6,000 dogs with naturally occurring cancers. This provides an unprecedented view into canine cancer across the full spectrum of a dog’s cancer journey, from diagnosis to remission. It also gives our database a higher volume of data points closer to the decision boundary. Data here holds greater value as it contains critical information that can better inform treatment decisions and outcomes. Through FetchTM and our vast database, FidoCure decodes cancer. This means our AI-driven precision medicine platform better supports veterinarians by supplying them with the most suitable therapies for each patient.
Because the breadth and quality of our dataset is so high, and the genetic diversity of dogs is much lower than humans, we find patterns in the data others can’t due to their smaller sample sizes. We can marry the molecules to the platform. That means our evidence around dog cancer mutations and treatment effectiveness in each case enables us to offer more targeted therapies.
Unlike chemotherapy and radiation, which damage healthy cells alongside cancerous ones, targeted therapies focus on cancer cells. It also means a more comfortable treatment experience for both pet and pet parent. Our targeted therapies can be administered orally at home. This reduces the stress of frequent clinical visits and removes the need for special waste-handling precautions found in traditional treatments. Rather than donning protective equipment or designating specific treatment areas in your house, interactions remain natural and comfortable for all.
The real measure of success, of course, isn’t to be found in lab results or clinical trials, but in the continued wagging of tails and smiles of families who gain precious additional years together. Take Romulus, a Maremma who thrived for four additional years following his bone cancer diagnosis, thanks to FidoCure. Or Forrest, a Golden Retriever who likewise gained four more years of family companionship after his successful cancer treatment. These are more than statistics. They’re more birthdays celebrated, more walks enjoyed, and many more memories made.
When it comes to those we love, a second chance shouldn’t just mean more time, it should mean a better time.